Abstract
There are many obstacles in the path of effective allergy management, in general, and allergic rhinitis (AR) control, in particular. Chief among them are: insufficient symptom relief in some patients provided by some currently considered first-line AR treatments in real life; an over-reliance on randomized controlled trials to direct AR guideline recommendations; the need for a broader interpretation of the AR evidence base (to include randomized controlled trials and real-life studies); poorly designed and interpreted studies; and lack of an AR control concept and common language of control. These controversies are fully reviewed here and challenging solutions have been presented.
Original language | English |
---|---|
Pages (from-to) | 1205-1217 |
Number of pages | 13 |
Journal | Expert Review of Clinical Immunology |
Volume | 11 |
Issue number | 11 |
Early online date | 29 Aug 2015 |
DOIs | |
Publication status | Published - 1 Sep 2015 |
Keywords
- allergic rhinitis
- clinical relevance
- control
- guidelines
- randomized controlled trials
- real life